Mangoceuticals Inc. reported new data on its antiviral compound MGX-0024 from three commercial poultry field trials in Tamil Nadu, India, involving about 29,000 broiler chickens given MGX-0024 in drinking water from around day 14 through market age. The company said no mortality in treated flocks was attributed to respiratory pathogens, with minimal deaths attributed mainly to heat stress; diagnostic confirmation relied on clinical observation and farm records, and PCR/serology testing was not uniformly applied. Mangoceuticals also cited a completed controlled H5N1 challenge study conducted at ICAR-NIHSAD under BSL-3 conditions (n=7 per group), where a 48-hour pre-treatment group showed reduced mortality versus controls and extended mean time to death, with intermittent low-level viral shedding in survivors. The company stated these results have already been issued in a late-2025 technical report and a final signed NIHSAD report and announced plans for additional multi-farm studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9659576-en) on February 23, 2026, and is solely responsible for the information contained therein.